MENU
+Compare
ACIU
Stock ticker: NASDAQ
AS OF
Apr 9, 11:20 AM (EDT)
Price
$1.47
Change
-$0.04 (-2.65%)
Capitalization
151.62M

ACIU AC Immune SA Forecast, Technical & Fundamental Analysis

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases... Show more

ACIU
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ACIU with price predictions
Apr 08, 2025

ACIU's Stochastic Oscillator is staying in oversold zone for 20 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ACIU advanced for three days, in of 227 cases, the price rose further within the following month. The odds of a continued upward trend are .

ACIU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACIU declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ACIU entered a downward trend on April 08, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.150) is normal, around the industry mean (12.887). P/E Ratio (0.000) is within average values for comparable stocks, (62.213). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.737). Dividend Yield (0.000) settles around the average of (0.026) among similar stocks. P/S Ratio (4.695) is also within normal values, averaging (241.309).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ACIU’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACIU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
ACIU
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ACIU is expected to report earnings to rise 24.64% to -20 cents per share on April 24

AC Immune SA ACIU Stock Earnings Reports
Q1'25
Est.
$-0.20
Q4'24
Beat
by $0.02
Q3'24
Beat
by $0.19
Q2'24
Missed
by $0.71
Q1'24
Missed
by $0.08
The last earnings report on March 13 showed earnings per share of -16 cents, beating the estimate of -18 cents. With 20.97K shares outstanding, the current market capitalization sits at 151.62M.
A.I. Advisor
published General Information

General Information

a developer of therapeutic and diagnostic products to prevent and modify diseases caused by misfolding proteins

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
EPFL Innovation Park
Phone
+41 213459121
Employees
161
Web
https://www.acimmune.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DNLDX50.77N/A
N/A
BNY Mellon Active MidCap A
MCGAX7.96N/A
N/A
Transamerica Mid Cap Growth A
GOGIX25.78N/A
N/A
JHancock International Growth I
EEMRX7.32N/A
N/A
MFS Emerging Markets Equity Research C
QASCX20.27-0.56
-2.69%
Federated Hermes MDT Small Cap Core A

ACIU and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ACIU has been loosely correlated with BDTX. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ACIU jumps, then BDTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACIU
1D Price
Change %
ACIU100%
-5.03%
BDTX - ACIU
54%
Loosely correlated
-8.09%
ARCT - ACIU
37%
Loosely correlated
-1.93%
RGNX - ACIU
35%
Loosely correlated
-10.46%
RCKT - ACIU
34%
Loosely correlated
-7.71%
FHTX - ACIU
33%
Poorly correlated
-12.77%
More